Retatrutide

Retatrutide – Triple Agonist Research Peptide

Retatrutide (LY3437943) is a next-generation investigational peptide that acts as a triple agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor) pathways simultaneously. It is intended strictly for laboratory and research purposes only.

Key Research Characteristics

• Mechanism: Simultaneous GLP-1, GIP, and glucagon receptor agonism
• Molecular Formula: C₂₂₂H₃₇₃N₅₇O₆₅S
• Molecular Weight: ~4,967 Da
• Purity: ≥98% (HPLC verified)
• Form: Lyophilised powder
• Storage: Store at -20°C; stable for 24 months when lyophilised
• Reconstitution: Bacteriostatic water recommended

Research Applications

Retatrutide is being studied in preclinical and clinical research contexts for its potential role in metabolic regulation, energy homeostasis, and body composition modelling. It is one of the most potent multi-receptor agonist peptides currently under investigation.

Quality Assurance

All Daza Enhanced peptides are 100% Australian lab tested with full Certificate of Analysis (CoA) available upon request. Each batch undergoes rigorous HPLC and mass spectrometry verification to ensure purity and identity.

⚠️ For Research Use Only. Not for human or veterinary use. Not for therapeutic, diagnostic, or food use. Must be handled by qualified research professionals in accordance with applicable regulations.